RecruitingNCT06278610

Pelvic Exenteration and Laterally Extended Pelvic Resection

Accuracy of Ultrasound Scan in Patients Undergoing Pelvic Exenteration and Laterally Extended Pelvic Resection


Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Enrollment

85 participants

Start Date

Nov 19, 2020

Study Type

OBSERVATIONAL

Conditions

Summary

Growing evidence in literature is supporting the role of ultrasound scan (US) as accurate tool in diagnosis and staging of gynecologic cancers. In particular, different studies demonstrated the accuracy of US in assessing endometrial, cervical, and ovarian cancer in the primary setting. However, the number of studies investigating the role of US in the recurrent setting is limited. Moreover, there is no evidence in literature exploring the role of US in laterally-extended pelvic recurrences from gynecologic cancer, where the Magnetic Resonance Imaging (MRI) scan is still considered the most accurate tool.


Eligibility

Sex: FEMALE

Inclusion Criteria5

  • All consecutive patients with histologically-proven recurrent or persistent gynecological cancer who are planned to undergo pelvic exenteration or laterally extended pelvic resection, both with curative and with palliative intent.
  • Anterior/total pelvic exenteration
  • Laterally extended endopelvic resection (LEER)
  • Laterally extended pelvic resection (LEPR) is defined as an en bloc lateral resection of a pelvic tumor involving sidewall muscle, and/or bone, and/or major nerve, and/or major vascular structure
  • With or without stoma formation

Exclusion Criteria2

  • Radical hysterectomy without lateral resection
  • Rectal resection only (posterior exenteration)

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTPELVIC EXENTERATION

PELVIC EXENTERATION


Locations(1)

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Roma, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06278610


Related Trials